[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Reuters_Health Reuters Health Reuters Health posts on X about novartis, $4502t, tariffs, $8750t the most. They currently have XXXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::25562183/interactions)  - X Week XXXXXX +61% - X Month XXXXXX +14% - X Months XXXXXXX -XX% - X Year XXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::25562183/posts_active)  - X Week XX +12% - X Month XX -XX% - X Months XXX -XX% - X Year XXXXX -XX% ### Followers: XXXXXXX [#](/creator/twitter::25562183/followers)  - X Week XXXXXXX -X% - X Month XXXXXXX -XXXX% - X Months XXXXXXX -XXXX% - X Year XXXXXXX -XXXX% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::25562183/influencer_rank)  ### Social Influence [#](/creator/twitter::25562183/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [novartis](/topic/novartis) #42, [$4502t](/topic/$4502t) #1, [tariffs](/topic/tariffs) 1.84%, [$8750t](/topic/$8750t) #27, [quarterly earnings](/topic/quarterly-earnings) #772, [saving](/topic/saving) 1.23%, [the early](/topic/the-early) 0.61%, [health insurance](/topic/health-insurance) 0.61%, [insurance](/topic/insurance) XXXX% **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) ### Top Social Posts [#](/creator/twitter::25562183/posts) --- Top posts by engagements in the last XX hours "AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer according to data announced on Saturday" [X Link](https://x.com/Reuters_Health/status/1979559366362620254) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-18T14:45Z 253.4K followers, XXX engagements "Japan's Takeda Pharmaceutical Co has signed a deal with Innovent Biologics to accelerate development of the Chinese drugmaker's oncology medicines it said on Wednesday" [X Link](https://x.com/Reuters_Health/status/1981084445277897215) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-22T19:45Z 253.4K followers, XXX engagements "CBC Group Asia's largest healthcare-focused asset manager has raised $XXX million for its second R-Bridge Healthcare Fund making it the region's biggest healthcare private credit fund the company said on Wednesday" [X Link](https://x.com/Reuters_Health/status/1978396740907585806) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-15T09:45Z 253.5K followers, XXX engagements "Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial" [X Link](https://x.com/Reuters_Health/status/1978698719508804022) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-16T05:45Z 253.5K followers, XXX engagements "Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial" [X Link](https://x.com/Reuters_Health/status/1978763042285297991) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-16T10:00Z 253.4K followers, XXX engagements "Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial" [X Link](https://x.com/Reuters_Health/status/1978827112606753065) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-16T14:15Z 253.5K followers, XXX engagements "AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial marking a potential breakthrough in one of the hardest-to-treat forms of the disease" [X Link](https://x.com/Reuters_Health/status/1979800960340824217) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-19T06:45Z 253.5K followers, XXX engagements "Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%" [X Link](https://x.com/Reuters_Health/status/1979929303996342570) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-19T15:15Z 253.5K followers, XXX engagements "Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%" [X Link](https://x.com/Reuters_Health/status/1979993528093606343) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-19T19:30Z 253.5K followers, 1047 engagements "Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%" [X Link](https://x.com/Reuters_Health/status/1980057651183599831) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-19T23:45Z 253.5K followers, XXX engagements "Swedish medical equipment maker Getinge reported third-quarter core earnings above market expectations on Tuesday supported by price adjustments to combat a hit from U.S. tariffs and negative currency exchange effects" [X Link](https://x.com/Reuters_Health/status/1980522004433269244) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-21T06:30Z 253.4K followers, XXX engagements "Swedish medical equipment maker Getinge beat quarterly earnings expectations on Tuesday aided by price hikes and cost saving measures meant to combat a hit from U.S. tariffs and negative currency exchange effects" [X Link](https://x.com/Reuters_Health/status/1980586164969992436) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-21T10:45Z 253.5K followers, XXX engagements "Swedish medical equipment maker Getinge beat quarterly earnings expectations on Tuesday aided by price hikes and cost saving measures meant to combat a hit from U.S. tariffs and negative currency exchange effects" [X Link](https://x.com/Reuters_Health/status/1980650475926999291) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-21T15:00Z 253.5K followers, XXX engagements "From Breakingviews - How Credit Suisse's CoCos could rise from the dead" [X Link](https://x.com/Reuters_Health/status/1979151681876086833) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-17T11:45Z 253.4K followers, XXX engagements "From Breakingviews - How Credit Suisse's CoCos could rise from the dead" [X Link](https://x.com/Reuters_Health/status/1979215982867398901) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-17T16:00Z 253.4K followers, XXX engagements "China's Innovent Biologics said on Wednesday it had signed an $XXXX billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate cancer therapies" [X Link](https://x.com/Reuters_Health/status/1980797555605749816) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-22T00:45Z 253.4K followers, XXX engagements "Japan's Takeda Pharmaceutical Co has signed a deal with Innovent Biologics to accelerate development of the Chinese drugmaker's oncology medicines it said on Wednesday" [X Link](https://x.com/Reuters_Health/status/1981020351346684390) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-22T15:30Z 253.4K followers, XXX engagements "WATCH: US family health insurance premiums jump X% to nearly $27000 in 2025 driven by higher spending on weight-loss treatments and prescriptions KFF reports. Workers pay $6850 on average with employers covering the rest" [X Link](https://x.com/Reuters_Health/status/1981174987873542505) [@Reuters_Health](/creator/x/Reuters_Health) 2025-10-23T01:45Z 253.4K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Reuters_Health Reuters Health
Reuters Health posts on X about novartis, $4502t, tariffs, $8750t the most. They currently have XXXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +61%
- X Month XXXXXX +14%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%
Mentions: XX #
- X Week XX +12%
- X Month XX -XX%
- X Months XXX -XX%
- X Year XXXXX -XX%
Followers: XXXXXXX #
- X Week XXXXXXX -X%
- X Month XXXXXXX -XXXX%
- X Months XXXXXXX -XXXX%
- X Year XXXXXXX -XXXX%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXX% finance XXXX%
Social topic influence novartis #42, $4502t #1, tariffs 1.84%, $8750t #27, quarterly earnings #772, saving 1.23%, the early 0.61%, health insurance 0.61%, insurance XXXX%
Top assets mentioned Novartis AG (NVS)
Top Social Posts #
Top posts by engagements in the last XX hours
"AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer according to data announced on Saturday"
X Link @Reuters_Health 2025-10-18T14:45Z 253.4K followers, XXX engagements
"Japan's Takeda Pharmaceutical Co has signed a deal with Innovent Biologics to accelerate development of the Chinese drugmaker's oncology medicines it said on Wednesday"
X Link @Reuters_Health 2025-10-22T19:45Z 253.4K followers, XXX engagements
"CBC Group Asia's largest healthcare-focused asset manager has raised $XXX million for its second R-Bridge Healthcare Fund making it the region's biggest healthcare private credit fund the company said on Wednesday"
X Link @Reuters_Health 2025-10-15T09:45Z 253.5K followers, XXX engagements
"Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial"
X Link @Reuters_Health 2025-10-16T05:45Z 253.5K followers, XXX engagements
"Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial"
X Link @Reuters_Health 2025-10-16T10:00Z 253.4K followers, XXX engagements
"Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial"
X Link @Reuters_Health 2025-10-16T14:15Z 253.5K followers, XXX engagements
"AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial marking a potential breakthrough in one of the hardest-to-treat forms of the disease"
X Link @Reuters_Health 2025-10-19T06:45Z 253.5K followers, XXX engagements
"Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%"
X Link @Reuters_Health 2025-10-19T15:15Z 253.5K followers, XXX engagements
"Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%"
X Link @Reuters_Health 2025-10-19T19:30Z 253.5K followers, 1047 engagements
"Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%"
X Link @Reuters_Health 2025-10-19T23:45Z 253.5K followers, XXX engagements
"Swedish medical equipment maker Getinge reported third-quarter core earnings above market expectations on Tuesday supported by price adjustments to combat a hit from U.S. tariffs and negative currency exchange effects"
X Link @Reuters_Health 2025-10-21T06:30Z 253.4K followers, XXX engagements
"Swedish medical equipment maker Getinge beat quarterly earnings expectations on Tuesday aided by price hikes and cost saving measures meant to combat a hit from U.S. tariffs and negative currency exchange effects"
X Link @Reuters_Health 2025-10-21T10:45Z 253.5K followers, XXX engagements
"Swedish medical equipment maker Getinge beat quarterly earnings expectations on Tuesday aided by price hikes and cost saving measures meant to combat a hit from U.S. tariffs and negative currency exchange effects"
X Link @Reuters_Health 2025-10-21T15:00Z 253.5K followers, XXX engagements
"From Breakingviews - How Credit Suisse's CoCos could rise from the dead"
X Link @Reuters_Health 2025-10-17T11:45Z 253.4K followers, XXX engagements
"From Breakingviews - How Credit Suisse's CoCos could rise from the dead"
X Link @Reuters_Health 2025-10-17T16:00Z 253.4K followers, XXX engagements
"China's Innovent Biologics said on Wednesday it had signed an $XXXX billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate cancer therapies"
X Link @Reuters_Health 2025-10-22T00:45Z 253.4K followers, XXX engagements
"Japan's Takeda Pharmaceutical Co has signed a deal with Innovent Biologics to accelerate development of the Chinese drugmaker's oncology medicines it said on Wednesday"
X Link @Reuters_Health 2025-10-22T15:30Z 253.4K followers, XXX engagements
"WATCH: US family health insurance premiums jump X% to nearly $27000 in 2025 driven by higher spending on weight-loss treatments and prescriptions KFF reports. Workers pay $6850 on average with employers covering the rest"
X Link @Reuters_Health 2025-10-23T01:45Z 253.4K followers, XXX engagements